KRAS and familial pancreatic carcinoma: The mutations in the following genes were found to be crucially connected with an increased incidence and progression of pancreatic cancer, protooncogenes such as KRAS, erbB-2 (receptor tyrosine kinase 2), and c-myc (cellular myelocytomatosis oncogene) and suppressor genes including CDKN2A (cyclin dependent kinase inhibitor 2A), TP53, and SMAD4, respectively [30,31].